Data Dose January 2025 #5

Metamizole and the Price of Pain Relief.

Pain relief is vital in healthcare, but what if the treatment poses its own risks? Metamizole, a potent non-opioid analgesic, remains controversial due to its effectiveness in managing pain and fever while carrying a severe risk of agranulocytosis—a potentially fatal drop in white blood cell counts. Read More...

India Approves Living Drug To Treat Blood Cancer: All About Qartemi And How It Works.

India has reached a significant milestone in blood cancer treatment with the approval of Qartemi, a groundbreaking CAR-T cell therapy developed by Bengaluru-based Immuneel Therapeutics. Designed for patients with advanced or relapsed B-cell Non-Hodgkin Lymphoma (B-NHL), this “living drug” offers new hope to those who have exhausted conventional treatment options. Read More...

The Side Effects of Inequality: How Lack of Diversity in Clinical Trials Affects Drug Effectiveness and Safety.

Medication plays a vital role in patient care, with most adults recognizing the benefits of new drug therapies. However, access to safe and effective treatments remains uneven. Beyond access, inequities start early in the drug development process. A lack of diversity in clinical trials continues to impact the safety and effectiveness of newly approved medications, highlighting a critical challenge in ensuring truly equitable healthcare. Read More...

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial.

Vigil Neuroscience has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 clinical trial set for Q3 2025. This move follows promising Phase 1 results, which confirmed the drug’s safety, tolerability, and pharmacokinetic profile, supporting its potential as a once-daily oral therapy for AD. This development marks a significant step forward in the search for effective Alzheimer’s treatments, offering new hope for patients and caregivers. Read More...